1 Cohen V, Khuri FR. Chemoprevention of lung cancer. Curr Opin Pulm Med, 2004, 10 (4): 279~283
2 Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin, 2004, 54 (3): 150~180
3 Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem, 2008, 15 (11): 1044~1071
4 Agarwal R, Deep G. Kava, a tonic for relieving the irrational development of natural preventive agents. Cancer Prev Res, 2008, 1 (6): 409~412
5 Cao P (曹沛), Wu FE (吴凤锷), Ding LS( 丁立生). Advances in the studies on the chemical constituents and biologic activities for Anemone species. Nat Prod Res & Dev (天然产物研究与开发), 2004, 16 (6): 581~584
6 Liu LS (刘力生), Xiao XH (肖显华), Zhang LD (张龙弟), Zheng RL (郑荣梁), Wu FE (吴凤锷), Zhu ZQ (朱子清). Effects of anemodeanin A on DNA, RNA and protein of tumor cells in vitro and plasma cAMP in mice. Acta Pharmacol Sin (中国药理学报), 1985, 6 (3): 192~194
7 Liao X (廖循), Li BG (李伯刚), Gao XP (高小平), Guan JF (官家发), Ding LS (丁立生), Chen YZ (陈耀祖). Bioactive triterpenoidsaponins from Anemone davidii. Chin Tradit Herb Drugs (中草药), 2001, 32 (6): 493~496
8 Peng SL (彭树林), Liao X (廖循), Wang FT (王昉彤), Ding LS (丁立生). Antitumor effect of the saponins from Anemone davidii. Nat Prod Res & Dev (天然产物研究与开发), 2001,13(5):60~62
9 Ren FZ (任风芝), Zhang XX (张雪霞), Niu GY (牛桂云), Zhang L (张丽), Shan BE (单保恩), Liu GC (刘刚叁). Active antitumor constituents from Anemone raddeana Regel. Chin Tradit Herb Drugs (中草药), 2005, 36(12): 1975~1978
10 Wang MK (王明奎), Ding LS (丁立生), Wu FE (吴凤锷). Anti-tumor activity of crude saponin from Anemone raddeana Regel. Chin J Appl Environ Biol (应用与环境生物学报), 2008, 14 (3): 378~382
11 Wang MK (王明奎), Ding LS (丁立生), Wu FE (吴凤锷). Antitumor effects of raddeanin A on S1 80, H22 and U14 cell xenografts in mice. Chin J Cancer (癌症), 2008, 27 (9): 910~913
12 Tang Y, Simoneau AR, Xie J, Shahandeh B, Zi X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prevention Res, 2008, 1 (6): 439~451
13 Tang Y, Li X, Liu Z, Simoneau AR, Xie J, Zi X. Flavokawain B, a kava chalcone, exhibits robust apoptotic mechanisms on androgen receptor-negative, hormone-refractory prostate cancer cell lines and reduces tumor growth in a preclinical model. Intern J Cancer, 2010, 127 (8): 1758~1768
14 Tang Y, Simoneau AR, Liao W, Guo Y, Hoang BH, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Zi X. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Therapeutics, 2009, 8 (2): 458~468
15 Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH, Zi X. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer, 2010, 9: 162. PMID: 20573255
16 Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303 (5660): 1010~1014
17 Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem, 2004, 92 (4): 656~663
18 Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 2009, 8 (8): 627~644
19 Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem, 1998, 273 (50): 33533~33539
20 Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol, 2004, 16 (6): 670~678
21 Stiles BL. PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev, 2009, 61 (14): 1276~1282